Tag Archive | "cetuximab"
Strategy to conquer cancer drug resistance uncovered
Source: info.cancerresearchuk.org Author: staff US scientists have identified a way in which cancer cells can become resistant to the cancer drug cetuximab (Erbitux), and suggest that treatments that are already available might be able to overcome this resistance. Researchers from the Dana-Farber Cancer Institute in Boston, US, have been studying why some patients only experience short-term [...]
Continue reading...Hypersensitivity Reactions to Erbitux Caused by Tick Bites.
Friday, July 1, 2011
Source: Gastroenterology & Endoscopy News Hypersensitivity reactions to cetuximab (Erbitux, ImClone Systems/Bristol-Myers Squibb), a monoclonal antibody approved for use in colorectal cancer, are not caused by the drug itself but by preexisting immunoglobulin E (IgE) antibodies that may result from tick bites, researchers have found. Cetuximab, like other monoclonal antibodies, is generally associated with a [...]
Continue reading...Yale School of Medicine Researchers take a closer look at “smart drugs”
Thursday, May 19, 2011
Source: Yale University Some of the most effective and expensive cancer drugs, dubbed “smart drugs” for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients. In two related studies, Yale School of Medicine researchers examined one such driver, the EGF receptor (EGFR), and found that [...]
Continue reading...HPV and EGFR are hottest topics in head and neck cancer
Friday, May 13, 2011
Source: www.medscape.com Author: Zosia Chustecka The hottest topic in head and neck cancers is the role of human papillomavirus (HPV) in the disease, although there is also a lot interest in treatment with EGRF inhibitors, especially the second-generation products, according to an expert here at the European Society for Therapeutic Radiology and Oncology 11th Biennial [...]
Continue reading...Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data
Saturday, March 5, 2011
Source: http://oto.sagepub.com/ Authors: Travis D. Reeves, MD et al. Objective: To review the current state of the data on the use of cetuximab in head and neck squamous cell carcinoma (HNSCC). Data Sources: The National Center for Biotechnology Information’s PubMed and the Cochrane collection. Review Methods. Search terms included cetuximab and head and neck cancer. [...]
Continue reading...Rash prediction in lung cancer?
Wednesday, January 26, 2011
Source: www.medscape.com Author: Maurie Markman, MD Hello. I am Dr. Maurie Markman from Cancer Treatment Centers of America in Philadelphia. I wanted to briefly discuss with you a very interesting paper[1] that appeared online in The Lancet Oncology on December 20th, 2010, and will be in print soon. The paper was entitled “First-Cycle Rash and [...]
Continue reading...ASCO: Non-platinum regimen works in head, neck cancer
Sunday, June 6, 2010
Source: www.medpagetoday.com Author: Michael Smith, North American Correspondent, MedPage Today A novel non-platinum-based regimen was efficacious in recurrent or metastatic squamous cell head and neck cancer, researchers said. The combination of pemetrexed (Alimta) and bevacizumab (Avastin) yielded a response rate of 30% in a small single-arm trial, according to Athanassios Argiris, MD, of the University [...]
Continue reading...Boehringer Ingelheim will announce preliminary data in the area of head and neck cancer
Sunday, May 23, 2010
Source: pr-usa.net Author: press release Boehringer Ingelheim will announce preliminary data in the areas of head and neck cancer and non-small cell lung cancer (NSCLC) for one of the company’s investigational compounds, BIBW 2992. These data will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) annual meeting in [...]
Continue reading...Integration of epidermal growth factor receptor inhibitors with preoperative chemoradiation
Monday, May 3, 2010
Source: Clincancerres Author: Annelies Debucquoy1, Jean-Pascal Machiels2, William H. McBride3, and Karin Haustermans1 Corresponding Author: Annelies Debucquoy, Laboratory of Experimental Radiotherapy, Department of Radiation Oncology, CDG Building, Box 815, UH Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. Phone: 32-16-346900; Fax: 32-16-346905; E-mail:annelies.debucquoy@med.kuleuven.be. Abstract In many different cancer cell types, the epidermal growth factor receptor (EGFR) pathway becomes hyperactivated because [...]
Continue reading...Pitt researchers receive patent for new head and neck cancer treatment
Sunday, January 31, 2010
Source: www.healthcanal.com Author: staff Researchers from the University of Pittsburgh School of Medicine have been awarded a patent from the U.S. Patent and Trademark Office for the development of a new DNA therapy for head and neck cancers. The therapy targets the epidermal growth factor receptor (EGFR), a protein found on the surface of many [...]
Continue reading...- Accuracy of Dentists in the Clinical Diagnosis of Oral Lesions
- New Evaluation for HPV16 Related Cancers Using "Pap-Test Equivalent"
- New Study Indicates Tobacco Industry Was Aware of Their Own Products Dangers
- Increase in oral cancers linked to HPV
- Systems Strategies To Support Cancer Screening in U.S. Primary Care Practice
- Study Finds- Fewer Dying from Throat & Mouth Cancer in the U.S.
- UI professors: HPV editorial misses the mark
- Girls-Only Vaccine Could Be Best Weapon Against HPV
- Many Head and Neck Cancer Survivors Face Eating Problems
- The Gardasil Problem: How The U.S. Lost Faith In A Promising Vaccine
- hilllaguna: This reply originally posted on the Knight Science...
- Brian Hill: I wonder who paid for this bit of research to be d...
- Brian Hill: Maybe in the Netherlands this mathematical model f...
- Brian Hill: The foundation would like to commend the doctors w...
- Brian Hill: While these doctors have looked at an overview of ...
- Big Tobacco Spending More Than a Super PAC to Defeat Cancer Research
- Actor’s Diagnosis Puts Spotlight on Oral Cancer
- Actor Michael Douglas Partners With Oral Cancer Foundation For Early Detection PSA Campaign
- 2009 Federal Tobacco Tax Increase Cut Number of Youth Smokers by At Least 220,000 in First Two Months Alone, New Study Shows
- Radiotherapy May Be Enough for HPV-Positive Throat Cancer
- Stem cell sparing radiotherapy for head and neck cancer may avoid salivary gland damage
- 1 of 6 cancer deaths worldwide caused by preventable infections
- Vaccination rates higher in states requiring them in middle school
- Tobacco Smoking and Increased Risk of Death and Progression for Patients With p16-Positive and p16-Negative Oropharyngeal Cancer
- Beastie Boys Co-Founder Adam Yauch Dead at 47
Follow OCF on these social networking sites connect to us, get involved, spread the knowledge, help the cause, change the world.
Friday, September 9, 2011
0 Comments